Innate Pharma SA (OTCMKTS:IPHYF) Sees Large Growth in Short Interest

Innate Pharma SA (OTCMKTS:IPHYF) was the recipient of a significant increase in short interest in May. As of May 15th, there was short interest totaling 23,016 shares, an increase of ∞ from the April 30th total of 0 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 36 shares, the days-to-cover ratio is currently 639.3 days.

Innate Pharma Price Performance

Innate Pharma stock remained flat at $1.65 during mid-day trading on Monday. The company has a fifty day simple moving average of $1.63 and a two-hundred day simple moving average of $1.94. Innate Pharma has a twelve month low of $1.37 and a twelve month high of $2.25.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.